Biology Information Open Source's promoter, Richard Jefferson, asserts that BIOS is explicitly modelled after the Open Source initiative in software. But science is grounded in open exchange and the sharing of information, so what is the point of BIOS and other initiatives such as Science Commons?

Software agents could change the way that computing works. You just leave them to get on with the work.

Universities in Ireland can now bid for funds to beef up their knowledge transfer activities.

Every business has to issue a press release one day. When they do so, they should remember that jargon does not help get the message across.

In an earlier blog, I deplored the lack of data about the European IP market and in particular about the academic licensing business. I am delighted to report that my “bottle in the ocean” approach has produced results.

Advances in neuroscience are opening up the treatment options for central nervous system diseases - at the same time as the ageing population is increasing the market for these products.

Drug companies finally have an incentive to carry out safety testing in children following new EU legislation approved last week.

The first protein drug extracted from the milk of a genetically modified animal has finally received European approval.

The TeGenero drug trial is complete, and an ongoing study is examing whether trial requirements should be changed. But, asks Nuala Moran, should the trial ever have been approved?

The Open Source software movement has broken the stranglehold of expensive, proprietary products. Could the same thing happen in biotechnology?